The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).
GVHD
GVL
MDSCs
NS cells
allo-HCT
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
11 May 2021
11 May 2021
Historique:
received:
08
03
2021
revised:
02
05
2021
accepted:
06
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
Myeloid-derived suppressor cells (MDSCs) are implicated in the complex interplay involving graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) in hematologic malignancies. A review of literature through PubMed was undertaken to summarize the published evidence on the pathophysiology and clinical implications of MDSCs in allo-HCT. Literature sources published in English since 1978 were searched, using the terms Natural Suppressor (NS) cells, MDSCs, GVHD, and allo-HCT. In vivo studies demonstrated that MDSCs derived from mobilization protocols could strongly suppress allo-responses mediated by T cells and enhance T-Reg activity, thus inhibiting GVHD toxicity. However, the influence of MDSCs on the GVL effect is not fully defined. The induction or maintenance of MDSC suppressive function would be advantageous in suppressing inflammation associated with GVHD. Pathways involved in MDSC metabolism and the inflammasome signaling are a promising field of study to elucidate the function of MDSCs in the pathogenesis of GVHD and translate these findings to a clinical setting.
Sections du résumé
BACKGROUND
BACKGROUND
Myeloid-derived suppressor cells (MDSCs) are implicated in the complex interplay involving graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) in hematologic malignancies.
METHODS
METHODS
A review of literature through PubMed was undertaken to summarize the published evidence on the pathophysiology and clinical implications of MDSCs in allo-HCT. Literature sources published in English since 1978 were searched, using the terms Natural Suppressor (NS) cells, MDSCs, GVHD, and allo-HCT.
RESULTS
RESULTS
In vivo studies demonstrated that MDSCs derived from mobilization protocols could strongly suppress allo-responses mediated by T cells and enhance T-Reg activity, thus inhibiting GVHD toxicity. However, the influence of MDSCs on the GVL effect is not fully defined.
CONCLUSIONS
CONCLUSIONS
The induction or maintenance of MDSC suppressive function would be advantageous in suppressing inflammation associated with GVHD. Pathways involved in MDSC metabolism and the inflammasome signaling are a promising field of study to elucidate the function of MDSCs in the pathogenesis of GVHD and translate these findings to a clinical setting.
Identifiants
pubmed: 34064671
pii: jcm10102050
doi: 10.3390/jcm10102050
pmc: PMC8150814
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Subventions
Organisme : American Society of Hematology
ID : ASH Global Research Award
Références
Blood. 2017 Nov 23;130(21):2243-2250
pubmed: 28924018
Blood. 2014 Jul 17;124(3):374-84
pubmed: 24914139
Biol Blood Marrow Transplant. 2013 May;19(5):692-702
pubmed: 23376089
J Exp Med. 1985 Sep 1;162(3):979-92
pubmed: 3161977
Cell Immunol. 1990 May;127(2):260-74
pubmed: 1970279
Cancer Res. 2010 Jun 1;70(11):4335-45
pubmed: 20484028
Front Immunol. 2019 Jun 20;10:1369
pubmed: 31281314
Front Immunol. 2021 Mar 02;12:631365
pubmed: 33737934
Blood. 2010 Dec 16;116(25):5738-47
pubmed: 20807889
Bone Marrow Transplant. 2014 Feb;49(2):168-73
pubmed: 23892326
Cell Rep. 2016 Dec 20;17(12):3219-3232
pubmed: 28009291
J Immunol. 1984 Feb;132(2):971-8
pubmed: 6140288
Proc Natl Acad Sci U S A. 1978 Oct;75(10):5142-4
pubmed: 283421
Cancer Res. 2006 Jan 15;66(2):1123-31
pubmed: 16424049
Bone Marrow Transplant. 1996 Jul;18(1):53-61
pubmed: 8831996
Cells. 2020 Feb 27;9(3):
pubmed: 32121014
N Engl J Med. 2020 May 7;382(19):1800-1810
pubmed: 32320566
Blood. 2000 May 1;95(9):2754-9
pubmed: 10779417
Int J Stem Cells. 2018 Dec 31;12(1):73-83
pubmed: 30595008
J Clin Oncol. 2011 Jun 1;29(16):2230-9
pubmed: 21464398
J Hematol Oncol. 2019 Oct 22;12(1):105
pubmed: 31640764
Clin Exp Immunol. 2020 Dec;202(3):407-422
pubmed: 32681646
Leukemia. 2013 Feb;27(2):377-88
pubmed: 22828446
Blood. 1992 Dec 15;80(12):3242-50
pubmed: 1467527
Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S58-64
pubmed: 18545246
Blood. 2008 Oct 15;112(8):3508-16
pubmed: 18614760
Int Immunopharmacol. 2020 Nov;88:106929
pubmed: 32889240
Blood. 1997 Oct 15;90(8):3204-13
pubmed: 9376604
Sci Transl Med. 2015 Apr 1;7(281):281ra42
pubmed: 25834108
J Immunol. 2006 Apr 1;176(7):3877-83
pubmed: 16547218
Curr Opin Hematol. 2011 Nov;18(6):408-13
pubmed: 21912253
Int J Mol Sci. 2020 May 29;21(11):
pubmed: 32485958
Immunol Rev. 2008 Apr;222:180-91
pubmed: 18364002
Br J Haematol. 2019 Jul;186(1):60-71
pubmed: 30916396
Bone Marrow Transplant. 1988 Sep;3(5):379-86
pubmed: 3056545
Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63
pubmed: 22510384
Nat Med. 2015 Mar;21(3):248-55
pubmed: 25686105
J Clin Invest. 2001 Jun;107(12):1581-9
pubmed: 11413166
Int J Hematol. 2019 Nov;110(5):529-532
pubmed: 31586304
Blood. 2020 May 14;135(20):1739-1749
pubmed: 32160294
Cytokine. 2012 May;58(2):169-77
pubmed: 22277799
Nat Med. 2015 Mar;21(3):263-9
pubmed: 25686106
J Hematother. 1996 Aug;5(4):391-7
pubmed: 8877714
Biol Blood Marrow Transplant. 2008 Sep;14(9):973-984
pubmed: 18721760
Hemasphere. 2019 Jan 28;3(1):e168
pubmed: 31723807
Clin Immunol. 2012 Apr;143(1):83-7
pubmed: 22341087
Front Immunol. 2018 Oct 08;9:2207
pubmed: 30349527
Immunol Rev. 2010 Nov;238(1):37-46
pubmed: 20969583
Curr Opin Cell Biol. 2008 Apr;20(2):214-21
pubmed: 18329869
Oncoimmunology. 2018 Jul 30;7(10):e1494113
pubmed: 30288362
Bone Marrow Transplant. 1996 Jan;17(1):101-9
pubmed: 8673041
Clin Immunol. 2018 Feb;187:122-131
pubmed: 29132870
J Hematol Oncol. 2019 Mar 18;12(1):31
pubmed: 30885244
Annu Rev Immunol. 1984;2:219-37
pubmed: 6152690
Cancer Immunol Res. 2017 Jan;5(1):3-8
pubmed: 28052991
Blood. 1992 Jul 1;80(1):264-9
pubmed: 1611093
Blood. 2015 Aug 27;126(9):1138-48
pubmed: 26185131
Nat Rev Cancer. 2013 Oct;13(10):739-52
pubmed: 24060865
Transplantation. 2005 Apr 15;79(7):846-50
pubmed: 15818329
J Immunol. 1984 Jan;132(1):101-10
pubmed: 6228575
J Exp Med. 1985 Jul 1;162(1):297-310
pubmed: 3159827
Oncoimmunology. 2016 Oct 20;5(12):e1247135
pubmed: 28123883
J Immunol. 2009 May 1;182(9):5693-701
pubmed: 19380816
Immunology. 2009 Sep;128(1 Suppl):e632-40
pubmed: 19740324
Leukemia. 2019 Aug;33(8):2078-2089
pubmed: 30737483
Blood. 2007 Feb 15;109(4):1568-73
pubmed: 17023580
Bone Marrow Transplant. 2015 Jun;50(6):822-8
pubmed: 25798669
Blood. 2012 May 17;119(20):4786-97
pubmed: 22408260
Cancer Res. 1999 Jul 1;59(13):3107-11
pubmed: 10397252
Biol Blood Marrow Transplant. 2013 Jan;19(1):12-21
pubmed: 22771839
Blood. 1997 Mar 1;89(5):1629-34
pubmed: 9057645
J Hematol Oncol. 2017 Jul 4;10(1):135
pubmed: 28676100
J Exp Med. 2013 Sep 23;210(10):1899-910
pubmed: 23980097
Annu Rev Med. 2015;66:97-110
pubmed: 25341012
Bone Marrow Transplant. 2014 Apr;49(4):545-52
pubmed: 24464140
Biol Blood Marrow Transplant. 2014 Dec;20(12):2049-55
pubmed: 25246295
Biol Blood Marrow Transplant. 2019 Oct;25(10):1933-1943
pubmed: 31195137
Biol Blood Marrow Transplant. 2018 Dec;24(12):2381-2396
pubmed: 30006304
Blood. 2015 Sep 24;126(13):1621-8
pubmed: 26265697
J Clin Apher. 2011;26(5):276-85
pubmed: 21898572
Sci Transl Med. 2010 Jul 21;2(41):41ra52
pubmed: 20650872
Trends Immunol. 2016 Mar;37(3):208-220
pubmed: 26858199
J Immunol. 2005 Feb 15;174(4):1841-50
pubmed: 15699110
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
J Exp Med. 2005 Oct 3;202(7):931-9
pubmed: 16186186
Br J Haematol. 2012 Jul;158(1):30-45
pubmed: 22533831
Biol Blood Marrow Transplant. 2018 Jan;24(1):32-42
pubmed: 28844945
Am J Hematol. 2015 Jan;90(1):E9-E16
pubmed: 25303038
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Lancet Haematol. 2020 Feb;7(2):e157-e167
pubmed: 32004485
J Leukoc Biol. 2015 Dec;98(6):913-22
pubmed: 26337512
Nat Rev Immunol. 2021 Feb 1;:
pubmed: 33526920
Cancer Res. 2006 Jul 1;66(13):6807-15
pubmed: 16818658
J Exp Med. 2019 Sep 2;216(9):2150-2169
pubmed: 31239386
Blood. 2016 Mar 17;127(11):1502-8
pubmed: 26764356
Blood. 2019 Nov 7;134(19):1670-1682
pubmed: 31533918
Blood. 2015 Jul 2;126(1):103-12
pubmed: 25972159
Front Immunol. 2020 May 22;11:989
pubmed: 32528476
Nature. 2011 Jan 13;469(7329):221-5
pubmed: 21124315
J Clin Apher. 2018 Dec;33(6):654-660
pubmed: 30394564
Gastroenterology. 2008 Jul;135(1):234-43
pubmed: 18485901
Biol Blood Marrow Transplant. 2020 Sep;26(9):1738-1746
pubmed: 32447043
Nat Rev Immunol. 2012 May 11;12(6):443-58
pubmed: 22576252
Nat Med. 2010 Dec;16(12):1434-8
pubmed: 21102458
Cell Immunol. 2000 Dec 15;206(2):125-35
pubmed: 11161444
J Transl Med. 2020 Dec 14;18(1):483
pubmed: 33317573
J Immunol. 2009 Jan 1;182(1):240-9
pubmed: 19109155
Mucosal Immunol. 2016 May;9(3):730-43
pubmed: 26442657